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Abstract
Background: Prediction intervals can be calculated for predicting cancer incidence on the basis
of a statistical model. These intervals include the uncertainty of the parameter estimates and
variations in future rates but do not include the uncertainty of assumptions, such as continuation
of current trends. In this study we evaluated whether prediction intervals are useful in practice.
Methods: Rates for the period 1993–97 were predicted from cancer incidence rates in the five
Nordic countries for the period 1958–87. In a Poisson regression model, 95% prediction intervals
were constructed for 200 combinations of 20 cancer types for males and females in the five
countries. The coverage level was calculated as the proportion of the prediction intervals that
covered the observed number of cases in 1993–97.
Results: Overall, 52% (104/200) of the prediction intervals covered the observed numbers. When
the prediction intervals were divided into quartiles according to the number of cases in the last
observed period, the coverage level was inversely proportional to the frequency (84%, 52%, 46%
and 26%). The coverage level varied widely among the five countries, but the difference declined
after adjustment for the number of cases in each country.
Conclusion: The coverage level of prediction intervals strongly depended on the number of cases
on which the predictions were based. As the sample size increased, uncertainty about the adequacy
of the model dominated, and the coverage level fell far below 95%. Prediction intervals for cancer
incidence must therefore be interpreted with caution.
Background
Prediction of cancer incidence is of great interest for both
health authorities and the scientific community [1]. Esti-
mates of the future cancer burden should indicate the
appropriate amounts of resources that will be needed for
diagnosis, treatment and rehabilitation. Since quantifica-
tion of future cancer incidence is inherently uncertain [2],
some measurement of the uncertainty would be useful. It
has been suggested that, similar to the confidence inter-
vals calculated in standard statistical modeling, prediction
intervals should be presented with predictions of cancer
incidence [3,4].
When future cancer incidence is predicted in a statistical
model, three sources of uncertainty are associated with the
predicted numbers. The first is the variance of the param-
eters estimated in the model; the second is the random
variation of the future number of cases; and the third is
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the adequacy of the model. The last includes the uncer-
tainty in both the mathematical structure of the model
and the choice of projected components, such as whether
to assume that current trends will continue into the
future. The first two sources of variance can be included in
a statistical model. Intervals that are based only on the
variance of the parameters estimated in the model are
called 'confidence intervals', while intervals that also
encompass variation in the future number of cases are
called 'prediction intervals'.
The third source of uncertainty, variations caused by devi-
ations from the model assumptions, is difficult to formal-
ize. Engeland et al. [5] argued that "The large uncertainties
associated with the specification of the models used in the
predictions obviate the construction of confidence inter-
vals." One way of investigating the extent of the uncer-
tainty in specification of a model is to calculate prediction
intervals from historical data and then calculate the pro-
portion of those intervals that actually cover the observed
number of cancer cases. If the proportion is close to the
nominal level, e.g. 95 %, the prediction intervals could be
taken to give a fair description of the range of likely values
to be expected. A low proportion would indicate that
there was great uncertainty in the model assumptions,
and that prediction intervals should be interpreted with
caution. The aim of this study was to evaluate the extent
to which prediction intervals derived from incidence rates
can be expected to cover the actual numbers observed 10
years later.
Methods
Material
The material consisted of new cases of cancer reported to
the cancer registries of Denmark, Finland, Iceland, Nor-
way and Sweden between 1958 and 1997, and population
figures covering the same calendar period from the central
statistical offices in these countries. Sweden has the largest
population, with 8.9 million inhabitants, followed by
Denmark, Finland, Norway and Iceland with 5.3, 5.2, 4.5
and 0.3 million, respectively. The Nordic cancer registries
receive reports from physicians, hospitals, pathological
and cytological laboratories and (except in Sweden) death
certificates [6]. Compulsory reporting and information
from multiple sources ensure almost 100% completeness
of all the cancer registries [7].
Table 1 lists the cancer sites included in the study.
Detailed descriptions of the types of tumors at each site
that are included was given by Engeland et al. [5]. As there
were few cases of cancers of the lip and larynx among
women and of the breast among men, these cancers were
included in 'other sites'.
The data were tabulated in five-year age groups (0–4, 5–9,
..., 80–84, ≥ 85) and five-year calendar periods (1958–62,
1963–67, ..., 1993–97). Since there were 20 types of can-
cers for each sex and five countries in the study, we had
200 different combinations for which to make
predictions.
Statistical model
The age-period-cohort (APC) model [8] has been widely
used for predicting cancer incidence and mortality [9-13].
This Poisson regression model is based on tables with
five-year age groups and five-year calendar periods. Birth
cohorts were constructed synthetically by subtracting age
from period. The model can be written as
Rap = exp(Aa + D·p + Pp + Cc),
where Rap is the incidence rate in age group a in calendar
period p, D is the common drift parameter [14], Aa is the
age component for age group a, Pp is the non-linear period
component of period p and Cc is the non-linear cohort
component of cohort c, c = p - a. We used a slightly mod-
ified model [5], substituting a power link for the log link:
Rap = (Aa + D·p + Pp + Cc)5,
in order to level off the exponential growth in the multi-
plicative model. An empirical study of these two models
showed that the power model gave predictions that were
closer to the observed rates [2]. For some cancer sites for
which there were only a few cases in Iceland, a model
without the cohort component was used; see Engeland et
al. [5] for details and on the lower limits of the age groups
included for each site in all the countries.
To ensure a reasonable fit of each data set to the model,
the number of five-year periods on which the predictions
should be based on was chosen. First, a model including
the last six 5-year periods (1958–1987) was fitted. If the
model was rejected by a test for goodness-of-fit (5% level),
a model including the last five periods was fitted. If this
model was also rejected, only the last four periods were
used.
Future non-linear effects of cohort and period were
assumed to be equal to the last estimated effect in the
model, and predictions were made by projecting the drift.
Numbers of cancer cases were predicted by multiplying
the predicted rates by the person-years at risk in a given
age group and time period.
Prediction intervals, coverage level and discrepancy ratio
In an article on the precision of cancer incidence predic-
tions, Hakulinen and Dyba [3] derived prediction inter-
vals for Poisson distributed variables. Following theirBMC Medical Research Methodology 2005, 5:21 http://www.biomedcentral.com/1471-2288/5/21
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paper, let  , where a is the age group, f is the
future calendar period for which predictions are to be
made (f = 8 which corresponds to the period 1993–97),
Raf is the incidence rate in age group a in period f, and kaf
and naf are the corresponding number of cases and person-
years, respectively. Further, let the expected number of
cases, E(kaf), be defined as λ af = naf (Aa + D·P + Pf + Cc)5,
and let   and  . The variance of the
future number of cases, var (kf), can be written as var (kf)
= var ( ) + σ 2 E( ). The first component, var ( ),
reflects the uncertainty in estimating the parameters in the
model. The second component, σ 2 E( ), reflects the ran-
dom variation of the future number of cases for a Poisson-
distributed variable, allowing for extra-Poisson variation,
i.e., σ 2 measures the degree of over-dispersion.
An estimator for the variance of the future number of
cases can be found by using Taylor series expansion of
non-linear functions (see formulas in the appendix). A
Table 1: Proportions of observed numbers of cases in 1993–97 covered by prediction intervals based on trends up to 1987, by site, sex, 
country and frequency*.
Number of intervals Coverage number (%) P-value for difference
Site 0.54
Lip 5 2 (40)
Tongue, oral cavity and pharynx 10 5 (50)
Oesophagus 10 5 (50)
Stomach 10 5 (50)
Colon 10 7 (70)
Rectum 10 5 (50)
Pancreas 10 6 (60)
Larynx 5 3 (60)
Lung 10 4 (40)
Breast 5 2 (40)
Cervix uteri 5 2 (40)
Corpus uteri 5 2 (40)
Ovary 5 1 (20)
Prostate 5 2 (40)
Testis 5 4 (80)
Kidney 10 7 (70)
Urinary bladder 10 5 (50)
Melanoma of the skin 10 3 (30)
Thyroid 10 7 (70)
Non-Hodgkin lymphomas 10 4 (40)
Hodgkin disease 10 9 (90)
Multiple myeloma 10 4 (40)
Acute leukaemia 10 7 (70)
Other sites 10 3 (30)
Sex 0.67
Male 100 50 (50)
Female 100 54 (54)
Country <0.001
Denmark 40 18 (45)
Finland 40 21 (53)
Iceland 40 35 (88)
Norway 40 20 (50)
Sweden 40 10 (25)
Frequency <0.001
≤  70 per year 50 42 (84)
> 70 and ≤  230 per year 50 26 (52)
> 230 and ≤  555 per year 50 23 (46)
> 555 per year 50 13 (26)
*Average number of cases per year in the period 1983–87, grouped into four quartiles.
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95% prediction interval for the future number of cancer
cases, kf, can then be calculated from an assumption of
normality:
where kf was estimated by  .
On the basis of up to six 5-year periods between 1958 and
1987, prediction intervals for the numbers of cases in the
period 1993–97 were calculated for all 200 combinations
of 20 sites for each sex in each of the five countries. The
coverage level was defined as the proportion of the predic-
tion intervals that covered the observed number of cases
in 1993–97.
The coverage level only indicates whether the observed
number of cases was inside the prediction interval or not.
Additional information can be gained by looking at how
far outside of the interval the observations fall. Discrep-
ancy ratio was defined as the absolute distance between
observed and predicted number of cases, measured in half
prediction interval widths:
where   and  kf are the predicted and observed number
of cases, respectively, and   is the distance
between predicted number of cases and the limit of the
prediction interval. Figure 1 illustrates the discrepancy
ratio. When the discrepancy ratio is larger than 1, it meas-
ures how much wider the prediction interval had to be to
cover the observed number of cases. In Figure 1, the
observed number of cases is about twice as far from the
predicted number compared to the lower limit of the pre-
diction interval, giving a discrepancy ratio of 2.
Fisher's exact test was used to evaluate differences between
sites, countries and quartiles of number of cases. A bino-
mial regression model was used to study the effect of
country and frequency simultaneously.
Results
Prediction intervals were calculated from data up to 1987
for the 200 combinations of sex, site and country. After
observing the number of cases 10 years later, in the period
1993–97, 104 (52%) of the observed numbers were cov-
ered by the prediction intervals. Coverage levels for spe-
cific sites varied from 20% to 90%, but only five or ten
intervals were calculated for each site and the difference
between the sites was not statistically significant (Table 1).
The coverage levels for the five Nordic countries varied
widely. For the country with the smallest population, Ice-
land, the coverage level was 88%, which is relatively close
to the nominal level of 95%. The levels for Denmark, Fin-
land and Norway were around 50 %, while that for Swe-
den, the most populous country, was only 25%. When the
200 different predictions were ranked according to the
annual number of cases in the period 1983–87 (fre-
quency), the cut-offs for the four quartiles were 70, 230
and 555. Subdividing the predictions according to these
quartiles, the coverage level decreased markedly with the
annual number of cases, being 84% for the first quartile
and 52%, 46% and 26% for the next three, respectively
(Table 1).
Table 2 shows the associations between country and cov-
erage level as odds ratios (ORs), where the odds of cover-
ing the observed number of cases with the prediction
intervals in each country was calculated relative to the
odds in Denmark. The crude numbers reflect the pattern
seen in Table 1, the chance of the observed number of
cases being within the prediction interval being similar in
Denmark, Finland and Norway, higher in Iceland and
lower in Sweden. In the binomial regression model the
logarithm of the annual number of cases in 1983–87 was
used instead of the frequency itself or the quartiles of the
numbers. The reason for this was that the fit to the model
was worse when the frequency variable was entered on a
The discrepancy ratio Figure 1
The discrepancy ratio. Illustration of the components of 
the discrepancy ratio. The discrepancy ratio compares the 
distance between predicted and observed number of cases 
with the distance between predicted number and the limit of 
the prediction interval.
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linear rather than on a log-linear scale. Also, entering the
variable as four categories instead of as a continuous vari-
able did not further improve the fit. The OR for the loga-
rithm of the frequency was 0.52, indicating that an
increase of one unit on the log scale of the frequency
reduced the chance of covering the observed number of
cases by about 50%. When country and frequency were
mutually adjusted for in a multiple binomial regression
analysis, the effect of country declined and became non-
significant, while the effect of frequency remained almost
unchanged. In the univariate analysis, the OR for Iceland
relative to Denmark was 8.5 (95 % confidence interval
(CI): 2.8 – 26), which was reduced to 1.7 (95 % CI: 0.4 –
7.6) in the adjusted analysis. The coverage level for Swe-
den remained lower, with OR = 0.49 (95 % CI: 0.2 – 1.3)
for Sweden relative to Denmark.
The distribution of the discrepancy ratio for each country
is plotted in Figure 2. For Iceland, most of the discrepancy
ratios were below 1, corresponding to a coverage level of
88%. Of the 12 % with a higher discrepancy ratio, none
was more than 50 % outside of the prediction interval. In
Finland and Norway, observed numbers of cases fell up to
tree times further from the predicted numbers compared
to the limits of the prediction intervals, while in Denmark
and Sweden some predictions were 5–6 times outside of
the intervals.
Discussion
The coverage levels in the five Nordic countries differed
mainly as a function of the numbers of cases that formed
the basis for the predictions. In Iceland, where there were
generally few cases, the coverage level calculated from
95% prediction intervals was 88% while that in the other
Nordic countries, which had much more cases, was of
only 25–53%. The problem associated with interpretation
of prediction intervals is illustrated in Figure 3, where the
observed age-standardized (World standard [15]) inci-
dence rates for cancer of the lung in women in Iceland and
Denmark are plotted against the predicted rates, with 95
% prediction intervals. Although the difference between
the observed and predicted rates was smaller in Denmark
than in Iceland, the wide prediction interval for Iceland
meant that the observed rate in 1993–97 was covered by
the interval constructed for Iceland, but the narrower
interval for Denmark failed to cover the observed rate for
that country.
A statistical model is only a simplification of true under-
lying associations between variables. The finding that the
coverage level is inversely proportional to the sample size
can be explained by considering the difference between
the modeled (simplified) and true (complex) relationship
between the cancer rate and the explanatory variables age,
period and cohort. When the sample size increases, devi-
ations between the modeled and true relationship will
dominate, and non-overage will become a problem. It is
useful to distinguish between calculations of prediction
intervals for values within the observed range of values of
the explanatory variables (interpolation), and outside the
range (extrapolation). The non-coverage problem is even
larger for extrapolations, because they also relay on the
assumption of continuation of current trends. Another
difference between interpolation and extrapolation is that
when the sample size increases, the possibility to improve
the model increases. This would then reduce the non-cov-
erage problem for interpolations, by reducing the distance
between the true and the modeled relationship between
the variables. Extrapolations, on the other hand, consist of
making predictions for values of the covariates outside the
range of observed values. Thus, we have to make
assumptions that cannot be evaluated from the observed
data and the problem with non-coverage for extrapola-
tions are not necessarily reduced by improvements in the
model.
Table 2: Odds ratios (ORs) with corresponding 95% confidence intervals (CIs) for covering the observed number of cases in the period 
1993–97 with the prediction intervals calculated from trends up to 1987.
Crude Adjusted*
OR 95 % CI P-value OR 95 % CI P-value
Country < 0.001 0.39
Denmark 1.00 Reference 1.00 Reference
Finland 1.35 0.56 – 3.2 1.18 0.47 – 2.9
Iceland 8.54 2.8 – 26.3 1.72 0.39 – 7.6
Norway 1.22 0.51 – 2.9 1.08 0.43 – 2.7
Sweden 0.41 0.16 – 1.1 0.49 0.18 – 1.3
Log(frequency)§ 0.52 0.41 – 0.66 < 0.001 0.60 0.44 – 0.83 0.02
*Both variables included in the model.
§Logarithm of average number of cases per year in the period 1983–87.BMC Medical Research Methodology 2005, 5:21 http://www.biomedcentral.com/1471-2288/5/21
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It could be argued that a low coverage level indicates that
the model is not appropriate, rather than that calculation
of predication intervals is per se misleading. With the
possible exception of tobacco and lung cancer, few associ-
ations are strong enough to be modelled directly. Instead,
we used calendar period and birth cohort as proxy varia-
bles for changes in underlying risk factors in the model.
Møller et al. [2] found that the method used in this study
performed fairly well in comparison with other methods
currently in use for predicting cancer incidence, and that
all the methods evaluated missed the observed number of
cases by 10–15% on average for 10 year predictions. Pre-
diction methods could therefore be improved to increase
the overall coverage level, although it would be unreason-
able to expect that the correct model, or close to it, could
be specified for all cancer sites. As long as predictions are
based on some type of extrapolation from a statistical
model, the coverage level will generally decrease as a func-
tion of sample size. The problem is that at the time when
the prediction intervals are calculated, the appropriate-
ness of the model with respect to extrapolation into the
future usually cannot be evaluated. Prediction intervals
can thus be misleading, if they are interpreted as the range
of likely values for the number of cases to be expected.
The number of cases from which the predictions for the
different cancer sites were made varied widely. Cancers at
some sites are very common, like those of the prostate,
lung and breast, while others occur less frequently.
Because the coverage levels vary with frequency, we would
also have expected them to vary by site. The differences
were not, however, statistically significant, probably
because of the small number of prediction intervals calcu-
lated for each site.
A relatively large sample size was associated with a narrow
prediction interval, as seen for lung cancer among women
in Denmark (Figure 3). The prediction intervals are based
on asymptotic theory, which can result in underestimates
of variance. Bootstrapping is a suitable method for inves-
tigating this problem [16]. We constructed a 95% predic-
tion interval by bootstrapping the data for lung cancer
among women in Denmark, assuming that each cell fol-
lowed a binomial distribution in which the incidence rate
and the number of person-years at risk were used as prob-
ability of success and number of trials, respectively. We re-
sampled the data 1000 times, calculating the predicted
world-standardized incidence rate each time. The 95%
bootstrap interval, calculated by selecting the 2.5 and 97.5
percentiles of the 1000 predictions, was 32.7 – 36.7,
which is fairly close to the asymptotic interval of 32.6–
36.8. This indicates that the asymptotic intervals
calculated in this study describe the uncertainty in the pre-
dicted number of cases well, given a correctly specified
model.
Empirical distribution of discrepancy ratio Figure 2
Empirical distribution of discrepancy ratio. Empirical 
distribution of discrepancy ratio by country. Predictions for 
the 40 combinations of 20 sites for each sex constitute the 
distribution in each country.BMC Medical Research Methodology 2005, 5:21 http://www.biomedcentral.com/1471-2288/5/21
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Population forecasts are needed for predicting the
number of cancer cases. In this paper, we assumed that
these numbers were known, but in reality they constitute
a separate source of uncertainty. Population forecasts are
themselves extrapolations, relying on assumptions about
future migration patterns, birth rates and death rates. If
our projections for 1993–97 had been calculated from
population forecasts in 1987, the coverage levels would
probably have been even lower.
Most of the differences in coverage level among the five
countries disappeared when the number of cases was con-
trolled for. The remaining difference was not significant,
but the probability of covering the rates with prediction
intervals for Sweden continued to be lower after adjust-
ment of sample size. Møller et al. [2] showed that the
predictions for Sweden were more different from the
observed number of cases in 1993–97 than those in the
other countries, measured as the median of the absolute
value of the relative difference between the predicted and
observed numbers of cases. This explains the lower cover-
age level for Sweden, and indicates that the trends current
in 1987 continued to a lesser extent in Sweden than in the
other countries.
Engeland and co-workers [5] were reluctant to include
prediction intervals with their predictions of cancer inci-
dence in the Nordic countries. A similar view was
expressed both with regard to an update of predictions for
the Nordic countries [17], and to a prediction of cancer
incidence in New South Wales, Australia [18]. There are,
however, some instances where prediction intervals can
be of value. In cancer surveillance, inclusion of prediction
intervals in a routine comparison of the latest observed
rates with rates predicted from previous trends, can help
to identify changes in the rates beyond random variation.
The potential reasons for any discrepancy between the
observed and predicted rates can then be studied, includ-
ing changes in risk factors, diagnostic methods or inter-
ventions such as screening programs. In Finland,
predicted values with prediction intervals for 1980 were
calculated based on rates up to 1968 and compared to
observed number of cases in 1980 [19]. Of 33 prediction
intervals, 22 (67%) covered the observed values, and the
authors discussed possible reasons for those cancers
where the prediction intervals failed to cover the observed
number of cases. Prediction intervals can also be used to
identify highly uncertain predictions. For instance, 26
male cancer cases of the lip were predicted in Iceland in
the period 1993–97, and the 95 % prediction interval was
6–46 cases.
Conclusion
We do not recommend use of prediction intervals when
the predictions are used for administrative purposes, like
planning appropriate amounts of resources for diagnosis,
Illustration of prediction interval Figure 3
Illustration of prediction interval. Age standardized (World population) incidence rates of lung cancer among women in 
Iceland and Denmark. Predicted rates based on observed rates up to 1987, with corresponding 95% prediction interval for the 
period 1993–97 for each country.
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treatment and rehabilitation, as the intervals can give a
false impression of the precision of the predictions. When
predictions are based on larger numbers of cases, the
uncertainty in estimating the parameters of the model and
the random variation of the future rates are decreased.
Even relatively minor deviations in the assumptions can
then result in observed rates in the future that are outside
the range of likely values indicated by the prediction
interval.
Appendix
A 95 % prediction interval for the future number of cancer
cases, kf, can be calculated on the basis of an assumption
of normality:   were kf can be estimated
by  . The variance of kf  can be written
, and   and   can be estimated by
Taylor series expansion of non-linear functions:
Further, the parameter for over-dispersion, σ 2, can be esti-
mated from the ratio between the residual deviance of the
model and the corresponding number of degrees of free-
dom [20], and   can be estimated by
. We used the statistical pack-
age R in the calculations, and the variances and covari-
ances of the estimates of the parameters in the model were
found in the covariance matrix of the glm-object.
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